BHB
AXSM icon

Bank Hapoalim BM’s Axsome Therapeutics AXSM Stock Holding History

Bank Hapoalim BM’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,750
Closed -$213K – 120
2025
Q3 		$213K Buy
+1,750
New +$197K 0.03% 115
2025
Q2 		– Sell
-1,750
Closed -$204K – 125
2025
Q1 		$204K Buy
+1,750
New +$199K 0.03% 119
2021
Q1 		– Sell
-2,915
Closed -$237K – 232
2020
Q4 		$237K Hold
2,915
– – 0.03% 188
2020
Q3 		$208 Hold
2,915
– – 0.01% 166
2020
Q2 		$240K Sell
2,915
-1,335
-31% -$103K 0.06% 163
2020
Q1 		$250K Hold
4,250
– – 0.08% 144
2019
Q4 		$439K Buy
+4,250
New +$172K 0.1% 119

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank Hapoalim BM's AXSM Position: Q4 2025 in Review

Bank Hapoalim BM sold out of Axsome Therapeutics (AXSM) in Q4 2025, closing a stake of 1,750 shares — an estimated $213K sold.

Bank Hapoalim BM first reported a position in AXSM in Q4 2019 and held it in 7 quarters. The position peaked at $439K in Q4 2019. 398 funds tracked by Wall St. Rank hold AXSM as of Q4 2025.

  • Bank Hapoalim BM reported no remaining Axsome Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bank Hapoalim BM sold 1,750 Axsome Therapeutics shares in Q4 2025, an estimated $213K.
  • Bank Hapoalim BM first reported a position in Axsome Therapeutics in Q4 2019 and held it in 7 quarters.
  • Bank Hapoalim BM's Axsome Therapeutics position peaked at $439K in Q4 2019.
  • 398 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2025.

Based on Bank Hapoalim BM's 13F filing for Q4 2025, filed 17 Feb 2026.